PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH)...
Read More Details
Finally We wish PressBee provided you with enough information of ( RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation )
Also on site :
- Be quiet, small man – Musk to Polish FM
- 'Love Is Blind' Season 8 Ends With a Surprise Engagement at the Reunion
- Israel cuts Gaza electricity supply ahead of new truce talks